HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.

2nd Edition of Global Conference on Gynecology & Women's Health

October 17-19, 2024 | Baltimore, Maryland, USA

October 17 -19, 2024 | Baltimore, Maryland, USA
Gynec 2024

Feifei Wang

Speaker at Womens Health Conference - Feifei Wang
Jiulongpo District People's Hospital, China
Title : Individualized treatment strategies for endometriosis: Comprehensive optimization of medication, surgery, and assisted reproductive technologies

Abstract:

Objective: This article aims to assess and compare the therapeutic outcomes of patients with endometriosis undergoing medication, surgery, and assisted reproductive technologies (ART). Special attention is given to their effectiveness in treating infertility and the selection of the optimal treatment approach based on individual patient characteristics.

Methods and Materials: This study is based on multiple research papers, including studies on the long-term recurrence rates of infertility in endometriosis, comparisons between surgery and ART in improving pregnancy rates, and comparative studies on infertility treatment in patients with endometriosis and polycystic ovary syndrome. Additionally, the latest developments in non-invasive diagnostics and non-surgical treatment methods are considered.

Results: In approximately 2/3 of cases, medication therapy proves successful. However, all medications have varying side effects, significantly influencing the selection and prescription of specific drugs. For infertility caused by endometriosis, ART provides an effective treatment modality, including in vitro fertilization (IVF) and related techniques. Different types of endometriosis, such as those combined with polycystic ovary syndrome, exhibit varying responses to treatment during ART cycles. The average follicle-stimulating hormone (FSH) dosage required is 2230.80 ± 614.09 IU for stage III/IV endometriosis and 1171.43 ± 547.42 IU for stage I/II. During ART cycles, the pregnancy rate (PR) for patients in stages I/II using GnRH agonists is highest at 50%, while for stage III/IV patients, it is lowest at 14.29%.

Conclusion: The treatment of endometriosis necessitates an individualized approach, considering the advantages and limitations of medication, surgery, and ART. Different types and severity levels of endometriosis may require distinct treatment methods. While surgical intervention may reduce recurrence rates, ART offers higher success rates in certain cases. Therefore, it is recommended to formulate a comprehensive treatment plan based on the specific circumstances of each patient. Additionally, the development of new non-invasive diagnostic and non-surgical treatment methods provides more choices for the management of endometriosis.

Audience Take Away: 

  • This research give a advice to clinical physicians that how to choose the best treatment for patients with endometriosis.
  • The results of this research are based on multiple research papers, so it could give physicians a plausible conclusion.
  • While surgical intervention may reduce recurrence rates, ART offers higher success rates in certain cases.

Biography:

Ms. Feifei Wang is a doctor-in-charge working in Jiulongpo Diatrict People’s Hospital. She is work as a doctor in department of obstetrics and gynecology for years, and she is specializes in gynecological tumors, endometriosis, gynecological diseases minimally invasive diagnosis and treatment.

Watsapp